The Effectiveness of Alemtuzumab Given in Combination With CHOP and ESHAP in Patients Newly Diagnosed With Peripheral T-Cell Lymphoma (PTCL)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

November 30, 2006

Study Completion Date

July 31, 2008

Conditions

Peripheral T-cell Lymphoma

Interventions

DRUG

CHOP regimen alternate with ESHAP regimen

CHOP alternate with ESHAP is given every 21 days for a total of 6 course.

DRUG

Alemtuzumab

Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.

Trial Locations (1)

King Chulalongkorn Memorial Hospital, Bangkok